Cancer Family
Malignant Genitourinary System Neoplasm
CI-CAN-00000233Explore in graph →
3,549 active trials61 approved drugs295 evidence items
- NCIt
- C156484
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000233Explore in graph →
Clinical trials
15,544 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,963)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05472532 | Evaluation of an Automated System to Culture Metastatic Patient Circulating Tumor Cells in Embryonated Chicken Eggs (in Ovo Culture)(INOVOLINE) | completed | N/A | 101 | Hospices Civils de LyonOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT06534008 | Strive Cardio for Endometrial Cancer Survivors | completed | N/A | 33 | Jess S. GorzelitzOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT04533672 | Multiparametric Magnetic Resonance Imaging (MRI) to Improve Bladder Cancer Staging and Treatment Decision-making(SBCT) | completed | N/A | 186 | University of ZurichOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT07232927 | Evaluation of Hemostatic Agents in Partial Nephrectomy(HEMOSTA-PN) | completed | N/A | 150 | Ankara UniversityOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT05383482 | Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1 | completed | Phase 1 / Phase 2 | 22 | Laekna LimitedINDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT06925113 | A Study to Investigate the Prevalence of Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ and Characterize the Clinicopathologic Features of Gynecologic Cancers in Taiwan(HERGYN) | completed | — | 509 | Daiichi SankyoINDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT03839524 | A Trial Evaluating TG4050 in Ovarian Carcinoma. | completed | Phase 1 | 64 | TransgeneINDUSTRY | 2 | Nov 14, 2025 | clinicaltrials |
| NCT03738228 | Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer | completed | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Nov 12, 2025 | clinicaltrials |
| NCT04272086 | Utility of Liposomal Bupivacaine Transversus Abdominal Plane Block for Open Myomectomy | completed | Phase 4 | 140 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT05220501 | Optimization of Prostate Biopsy - Micro-Ultrasound Versus MRI(OPTIMUM) | completed | N/A | 804 | Sunnybrook Health Sciences CentreOTHER | 8 | Nov 10, 2025 | clinicaltrials |
| NCT01676818 | Eribulin Mesylate in Treating Patients With Advanced or Recurrent Cervical Cancer | completed | Phase 2 | 32 | University of Southern CaliforniaOTHER | 1 | Nov 6, 2025 | clinicaltrials |
| NCT03734653 | Testosterone Therapy in Castration Resistant Prostate Cancer | completed | Early Phase 1 | 30 | University of Colorado, DenverOTHER | 1 | Nov 6, 2025 | clinicaltrials |
| NCT06345183 | Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients | completed | — | 327 | Bristol-Myers SquibbINDUSTRY | 1 | Nov 6, 2025 | clinicaltrials |
| NCT05978232 | NAVAH Impact on Radiation Therapy Completion in Black Breast & Prostate Cancer Patients | completed | N/A | 30 | Case Comprehensive Cancer CenterOTHER | 1 | Nov 5, 2025 | clinicaltrials |
| NCT06397040 | The Use of Remote Monitoring to Improve Patient-Reported Outcomes and Readmission Rates Following Radical Cystectomy(WATCH) | completed | N/A | 38 | University of PittsburghOTHER | 1 | Nov 5, 2025 | clinicaltrials |
| NCT02875548 | A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study(TRuST) | completed | Phase 1 / Phase 2 | 58 | Epizyme, Inc.INDUSTRY | 7 | Nov 4, 2025 | clinicaltrials |
| NCT02162732 | Molecular-Guided Therapy for Childhood Cancer | completed | N/A | 186 | Giselle ShollerOTHER | 2 | Nov 3, 2025 | clinicaltrials |
| NCT03860961 | Increasing the Dose of Survivorship Care Planning in Improving Care and Outcomes in Prostate Cancer Survivors Receiving Androgen Deprivation Therapy | completed | N/A | 550 | NRG OncologyOTHER | 1 | Nov 3, 2025 | clinicaltrials |
| NCT02111941 | Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer | completed | Early Phase 1 | 19 | Mayo ClinicOTHER | 1 | Oct 31, 2025 | clinicaltrials |
| NCT05311527 | UroLift System With SAbR for Prostate Cancer and BPH | completed | N/A | 15 | University of Texas Southwestern Medical CenterOTHER | 1 | Oct 31, 2025 | clinicaltrials |
| NCT06250751 | Behavioral Exercise TRaining for Men Undergoing Androgen Depr Therapy for Prostate Ca(BETR-PC) | completed | N/A | 27 | Virginia Commonwealth UniversityOTHER | 1 | Oct 31, 2025 | clinicaltrials |
| NCT03480646 | ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 175 | Constellation PharmaceuticalsINDUSTRY | 1 | Oct 29, 2025 | clinicaltrials |
| NCT02203695 | Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy | completed | Phase 2 | 86 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 28, 2025 | clinicaltrials |
| NCT06861504 | The Femscope Calm Collect Device | completed | N/A | 13 | University of MichiganOTHER | 1 | Oct 27, 2025 | clinicaltrials |
| NCT02294461 | An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Participants | completed | Phase 3 | 395 | Astellas Pharma IncINDUSTRY | 4 | Oct 24, 2025 | clinicaltrials |
| NCT07220499 | Whole Food Plant-based Diet to Improve Outcomes in Prostate Cancer | completed | N/A | 11 | Pacific Cancer CareOTHER | 1 | Oct 24, 2025 | clinicaltrials |
| NCT03325634 | Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Primary Ovarian or Uterine Cancer | completed | Phase 1 | 15 | University of Colorado, DenverOTHER | 1 | Oct 23, 2025 | clinicaltrials |
| NCT02159989 | Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 | 83 | National Cancer Institute (NCI)NIH | 1 | Oct 20, 2025 | clinicaltrials |
| NCT04049227 | Abemaciclib and Letrozole in Treating Patients With Endometrial Cancer | completed | Early Phase 1 | 27 | Northwestern UniversityOTHER | 1 | Oct 20, 2025 | clinicaltrials |
| NCT04386993 | De-escalated Conformal Radiation Expedited Sequentially With Chemotherapy for Endometrial Cancer(DeCRESCEndo) | completed | N/A | 25 | Washington University School of MedicineOTHER | 1 | Oct 20, 2025 | clinicaltrials |
| NCT04838613 | Study of Diagnostic Performance of [18F]CTT1057 in BCR(GuidePath) | completed | Phase 3 | 190 | Novartis PharmaceuticalsINDUSTRY | 4 | Oct 20, 2025 | clinicaltrials |
| NCT02141438 | Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer(REASSURE) | completed | — | 1,472 | BayerINDUSTRY | 20 | Oct 16, 2025 | clinicaltrials |
| NCT03507608 | Assessing Induction of Double Strand Breaks With Androgen Receptor Partial Agonist in Patients on Androgen Suppression | completed | Early Phase 1 | 25 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 16, 2025 | clinicaltrials |
| NCT05247853 | HPV Vaccine Effectiveness Study in Rwandan Women Living With HIV | completed | — | 3,127 | Montefiore Medical CenterOTHER | 1 | Oct 16, 2025 | clinicaltrials |
| NCT03580499 | Vitamin B6 in Reducing Hot Flashes in Participants With Prostate Cancer Undergoing Antiandrogen Therapy | completed | N/A | 43 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Oct 15, 2025 | clinicaltrials |
| NCT04025229 | High Intensity Interval Training in Endometrial Cancer | completed | N/A | 30 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Oct 15, 2025 | clinicaltrials |
| NCT03939689 | I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).(ARROW) | completed | Phase 2 | 120 | Progenics Pharmaceuticals, Inc.INDUSTRY | 2 | Oct 14, 2025 | clinicaltrials |
| NCT04363957 | Gynecologic Brachytherapy-Specific Educational Video | completed | N/A | 80 | University of California, San DiegoOTHER | 1 | Oct 14, 2025 | clinicaltrials |
| NCT05293496 | A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors | completed | Phase 1 | 31 | MacroGenicsINDUSTRY | 1 | Oct 14, 2025 | clinicaltrials |
| NCT05523700 | Value-based Integrated Recommendation Software Guiding Ovarian Cancer Treatment (VIRGO2)(VIRGO) | completed | N/A | 10 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Oct 10, 2025 | clinicaltrials |
| NCT04169711 | Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma | completed | Phase 1 | 26 | Arrowhead PharmaceuticalsINDUSTRY | 1 | Oct 9, 2025 | clinicaltrials |
| NCT03253744 | Prostate SBRT for Locally Recurrent Prostate Cancer After Prior Radiotherapy | completed | Phase 1 | 17 | National Cancer Institute (NCI)NIH | 1 | Oct 8, 2025 | clinicaltrials |
| NCT06180460 | CALM: Managing Distress in Malignant Brain Cancer | completed | N/A | 60 | Virginia Commonwealth UniversityOTHER | 1 | Oct 8, 2025 | clinicaltrials |
| NCT03776812 | Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 178 | Corcept TherapeuticsINDUSTRY | 5 | Oct 7, 2025 | clinicaltrials |
| NCT04838626 | Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection(GuideView) | completed | Phase 2 / Phase 3 | 195 | Novartis PharmaceuticalsINDUSTRY | 5 | Oct 7, 2025 | clinicaltrials |
| NCT01812369 | Perioperative Chemotherapy for Patients With Locally Advanced Bladder Cancer(VESPER) | completed | Phase 3 | 500 | University Hospital, RouenOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT03460483 | Universal Endometrial Cancer DNA Sequencing for Detection of Lynch Syndrome and Personalized Care(OPTEC) | completed | N/A | 1,001 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT03914794 | A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors | completed | Phase 2 | 30 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT07206693 | Impact of PSA-based Screening on Mortality Among Men Aged 75-79: Target Trial Emulation | completed | — | 257,275 | Karolinska InstitutetOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT05755490 | PROWESS (PROstate Cancer Wearables Exercise and Structured Supports): A Pilot Supportive Care Intervention | completed | N/A | 14 | Massachusetts General HospitalOTHER | 1 | Oct 2, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Nov 20, 2025source: clinicaltrials